Analysed ALTAMIRA THERAPEUTICS LTD (CYTOF:OTCMKTS) News Sources
Altamira Therapeutics Announces Publication Highlighting Potential of RNA Nanoparticles for Disease-Modifying Treatment of Osteoarthritis
13-04-2026
yahoo.com
Altamira Therapeutics Provides Business Update and Reports Full Year 2025 Financial Results
31-03-2026
yahoo.com
Altamira Therapeutics Announces Release Date for 2025 Annual Report and Financial Statements
24-03-2026
yahoo.com
Altamira Therapeutics Announces Allowance of Japanese Patent Application Covering Bentrio Nasal Spray
13-02-2026
yahoo.com
Altamira Therapeutics Announces Market Approval of Bentrio Nasal Spray in China
19-12-2025
yahoo.com
Altamira Therapeutics Announces Certification of Bentrio Nasal Spray under Medical Device Regulation
20-11-2025
yahoo.com
Altamira Therapeutics Announces Successful Nanoparticle-Based Delivery of DNA Molecules
03-11-2025
yahoo.com
Altamira Therapeutics Provides Business Update and First Half 2025 Financial Results
29-08-2025
yahoo.com
What is the current price of ALTAMIRA THERAPEUTICS LTD (CYTOF:OTCMKTS)?
The current price of ALTAMIRA THERAPEUTICS LTD (CYTOF:OTCMKTS) is $0.0501.
ALTAMIRA THERAPEUTICS LTD (CYTOF:OTCMKTS) absolute price change since previous trading day?
The absolute price change of ALTAMIRA THERAPEUTICS LTD (CYTOF:OTCMKTS) since the previous trading day is $-0.0001.
ALTAMIRA THERAPEUTICS LTD (CYTOF:OTCMKTS) percentage price change since previous trading day?
The percentage price change of ALTAMIRA THERAPEUTICS LTD (CYTOF:OTCMKTS) since the previous trading day is -0.1992%.
What is the most recent average sentiment score for ALTAMIRA THERAPEUTICS LTD (CYTOF:OTCMKTS)?
The most recent average sentiment score for ALTAMIRA THERAPEUTICS LTD (CYTOF:OTCMKTS) is 86 out of 100.
What is the most recent average sentiment for ALTAMIRA THERAPEUTICS LTD (CYTOF:OTCMKTS)?
The most recent sentiment for ALTAMIRA THERAPEUTICS LTD (CYTOF:OTCMKTS) is .
SEC-8K** Filing Available For ALTAMIRA THERAPEUTICS LTD (CYTOF:OTCMKTS)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.